Gossamer Bio vs Keros Therapeutics
GOSS and KROS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GOSS and KROS compare
Keros Therapeutics is the larger company, worth 3.0 times as much as Gossamer Bio ($204M against $67.1M).
Gossamer Bio grew revenue faster over the last twelve months (78.0% versus −83.4% for Keros Therapeutics).
Keros Therapeutics keeps more of each dollar of sales as profit, with a net margin of −153% compared with −159% at Gossamer Bio.
Keros Therapeutics scores higher on the StockData Score (9 against 2 for Gossamer Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GOSS | KROS |
|---|---|---|
| Size and price | ||
| Market cap | $67.1M | $204M |
| Share price | $10.97 | $10.30 |
| Change, 1 year | −94.9% | −41.0% |
| Change, 5 years | −98.8% | −82.8% |
| Beta (5Y) | 1.58 | 1.11 |
| Employees | 161 | 78 |
| StockData Score | ||
| Total score | 2 | 9 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 0 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.9× (better) | 5.1× |
| P/B | – | 0.7× |
| FCF yield | −233% | −23.6% (better) |
| Fair value | – | $24.09 |
| Margin of safety | – | 57.3% |
| Growth | ||
| Revenue growth (TTM) | 78.0% (better) | −83.4% |
| Net income growth (TTM) | – | −196% |
| EPS growth (TTM) | – | −282% |
| Profitability | ||
| Operating margin | −140% (better) | −181% |
| Net margin | −159% | −153% (better) |
| FCF margin | −199% | −119% (better) |
| Return on equity | – | −12.6% |
| Return on invested capital | – | −389% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −10.3× | – |
| Current ratio | 0.60 | 18.14 (better) |
| Altman Z-score | −37.94 | 2.37 (better) |
| Piotroski F-score | 1 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 78.0% | 101% |
| Held by insiders | – | 53.3% |
| Insider net buying, 12 months | – | −$447K |
| Superinvestors holding | 1 | – |
| Short interest, % of float | – | 11.7% |
Go deeper
- GOSS stock overview
- GOSS income statement
- GOSS valuation and score
- KROS stock overview
- KROS income statement
- KROS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.